All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, Johnson & Johnson, Roche and sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Brentuximab vedotin in combination with ECADD approved by the EC for patients with ND Stage IIb/III/IV Hodgkin lymphoma
On June 3, 2025, the European Commission (EC) approved brentuximab vedotin, a CD30-directed antibody–drug conjugate, in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone (ECADD) chemotherapy, for the treatment of adult patients with newly diagnosed Stage IIb with risk factors/III/IV Hodgkin lymphoma.1 This approval follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on April 25, 2025.1
Brentuximab vedotin in combination with ECADD (BrECADD) was approved based on results from the phase III HD21 trial (NCT02661503), which were previously covered by the Lymphoma Hub.1 The co-primary safety and efficacy endpoints were met; BrECADD, when compared with bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (eBEACOPP), was associated with lower rates of treatment-related morbidity (42% vs 59%; relative risk, 0.72; p < 0.0001) and higher 4-year progression-free survival rates (94.3% vs 90.9%; hazard ratio, 0.66; p = 0.035).2
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
What types of support services or resources do you think would best facilitate the safe implementation of the BrECADD regimen in clinical practice?
